IP Library Granted Patent US 7,582,769
Granted Patent B2
US 7,582,769 · App. 11/994,728 · Granted Sep 1, 2009

Dicycloalkyl urea glucokinase activators

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,582,769
App. No.
11/994,728
Granted
Sep 1, 2009
Kind
B2
Abstract

Dicycloalkyl urea glucokinase activators compounds are glucokinase inhibitors useful for the treatment of diabetes. (I)

Claims (23)

1. A compound of formula (I)

wherein R 1 is

and R 2 is cyclohexyl; and

A is

and

R 5 is selected from the group consisting of C 3-6 -alkenyloxy, aryloxy-C 1-6 -alkyl, C 3-8 -cycloalkyl-C 1-6 -alkyloxy-C 1-6 -alkyl, aryl-C 1-6 -alkyloxy-C 1-6 -alkyl, heteroaryl-C 1-6 -alkyloxy-C 1-6 -alkyl, C 3-6 -alkenylthio, arylthio-C 1-6 -alkyl, C 3-8 -cycloalkyl-C 1-6 -alkylthio-C 1-6 -alkyl, or heteroaryloxy-C 1-6 -alkyl, each of which is optionally substituted with one or more substituents independently selected from R 12 , and wherein each aryl is phenyl and heteroaryl is pyridyl; and

R 12 is halogen, cyano, hydroxy, carboxy, —CF 3 , C 1-6 -alkyloxy, C 3-8 -cycloalkyloxy, aryloxy, aryl-C 1-6 -alkyloxy or C 1-6 -alkyl; and

R 8 is selected from halogen, carboxy, —CF 3 , —S—CH 3 , —S—CH 2 CH 3 , —S—CH 2 CH 2 CH 3 , methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, methoxy, ethoxy, —CH 2 —C(O)—O—CH 3 , —CH 2 —C(O)—O—CH 2 CH 3 , —CH 2 CH 2 —C(O)—O—CH 3 , —CH 2 CH 2 —C(O)—O—CH 2 CH 3 , —CH 2 —O—C(O)—CH 3 , —CH 2 —O—C(O)—CH 2 CH 3 , —CH 2 CH 2 —O—C(O)—CH 3 , —CH 2 CH 2 —O—C(O)—CH 2 CH 3 , —C(O)—O—CH 3 , —C(O)—O—CH 2 CH 3 , each of which is optionally substituted with one or more substituents independently selected from R 16 ; or heteroarylthio, wherein heteroaryl is pyridyl or imidazolyl, each optionally substituted on the heteroaryl part with one or more substituents independently selected from R 17 , or pyrrolidinyl, piperidyl, piperazinyl, or morpholinyl, each of which is optionally substituted with one or more substituents independently selected from R 16 ; or —S(O) 2 —NR 19 R 20 or —S(O) 2 —R 21

R 16 and R 17 are independently C 1-6 -alkyl, halogen, nitro, cyano, hydroxy, carboxy, oxo, —CF 3 , carboxy-C 1-6 -alkyl, hydroxy-C 1-6 -alkyl, —C 1-6 -alkyl-C(O)—O—C 1-6 -alkyl, —C 1-6 -alkyl-C(O)—NR 19 R 20 , —C(O)—O—C 1-6 -alkyl, —C(O)—C 1-6 -alkyl-C(O)—C 1-6 -alkyl, —NR 19 R 20 , —NHS(O) 2 C 1-6 -alkyl, —NHS(O) 2 CF 3 , —NHS(O) 2 CH 2 CF 3 , —C(O)NR 19 R 20 , —S(O) 2 C 1-6 -alkyl, —S(O) 2 CF 3 , —S(O) 2 CH 2 CF 3 or —S(O) 2 NR 19 R 20 ; and

R 19 and independently represent hydrogen, methyl, ethyl, or propyl, S(O) 2 —CH 3 , or R 19 and R 20 together with the nitrogen to which they are attached form a 3 to 8 membered heterocyclic ring with the said nitrogen atom, wherein the heterocyclic ring is pyrrolidyl, piperidyl, piperazinyl, homopiperazinyl, or morpholinyl, the heterocyclic ring is optionally substituted with one or more substituents independently selected from R 24 ; and

R 21 is selected from carboxy-methyl, carboxy-ethyl, or carboxy-propyl; and

R 24 is halogen, carboxy, C 1-6 -alkyl, carboxy-C 1-6 -alkyl, or —C(O)—O—C 1-6 -alkyl; and

as well as any salt hereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, racemic mixture, or any tautomeric forms thereof.

2. A compound according to claim 1 wherein R 5 is selected from the group consisting of C 3-6 -alkenyloxy, phenyloxy-C 1-6 -alkyl, benzyloxy-C 1-6 -alkyl, C 3-8 -cycloalkyl-C 1-6 -alkyloxy-C 1-6 -alkyl.

3. A compound according to claim 2 wherein R 5 is selected from the group consisting of C 3-4 -alkenyloxy, phenyloxy-methyl, benzyloxy-methyl, or cyclopropyl-methoxymethyl.

4. A compound according to claim 1 wherein R 12 is halogen, cyano, hydroxy, carboxy, —CF 3 , methoxy, ethoxy, propoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy, phenoxy, benzyloxy, phenyl-ethyloxy, phenyl-propoxy, methyl, ethyl or propyl.

5. A compound according to claim 4 wherein R 12 is halogen, carboxy, ethoxy, propoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy, phenoxy, benzyloxy, phenyl-ethyloxy, phenyl-propoxy, methyl, ethyl or propyl.

6. A compound according to claim 1 wherein R 8 is selected from Cl, —S—CH 3 , —S—CH 2 CH 3 , —S—CH 2 CH 2 CH 3 , —S—CH(CH 3 ) 2 , —S—CH 2 CH(CH 3 ) 2 , methyl, or ethyl, each of which is optionally substituted with one or more substituents independently selected from R 16 ; —S(O) 2 —NR 19 R 20 or —S(O) 2 —R 21 .

7. A compound according to claim 1 wherein R 16 and R 17 are independently C 1-6 -alkyl, halogen, hydroxy, oxo, carboxy, —CF 3 , carboxy-C 1-6 -alkyl, hydroxy-C 1-6 -alkyl, —C 1-6 -alkyl-C(O)—O—C 1-6 -alkyl, —C(O)—O—C 1-6 -alkyl, —NR 19 R 20 , —C(O)NR 19 R 20 or —S(O) 2 —C 1-6 -alkyl.

8. A compound according to claim 7 wherein R 16 and R 17 are independently methyl, ethyl, propyl, isopropyl, isobutyl, halogen, hydroxy, oxo, carboxy, —CF 3 , carboxy-methyl, carboxy-ethyl, carboxy-propyl, hydroxy-methyl, hydroxy-ethyl, hydroxy-propyl, —CH 2 —C(O)—O—CH 3 , —CH 2 —C(O)—O—CH 2 CH 3 , —CH 2 CH 2 —C(O)—O—CH 3 , —CH 2 CH 2 —C(O)—O—CH 2 CH 3 , —C(O)—O—CH 3 , —C(O)—O—CH 2 CH 3 , —C(O)—O—CH 2 CH 2 CH 3 , or —S(O) 2 CH 3 .

9. A compound according to claim 8 wherein R 16 and R 17 are independently methyl, ethyl, propyl, isopropyl, isobutyl, halogen, oxo, carboxy, carboxy-methyl, carboxy-ethyl, carboxy-propyl, hydroxy-methyl, hydroxy-ethyl, hydroxy-propyl, —CH 2 —C(O)—O—CH 3 , —CH 2 —C(O)—O—CH 2 CH 3 , —CH 2 CH 2 —C(O)—O—CH 3 , —CH 2 CH 2 —C(O)—O—CH 2 CH 3 , —C(O)—O—CH 3 , —C(O)—O—CH 2 CH 3 , —C(O)—O—CH 2 CH 2 CH 3 , or —S(O) 2 CH 3 .

10. A compound according to claim 7 wherein R 16 and R 17 are independently C 1-6 -alkyl, carboxy, —NR 19 R 20 , —C(O)—O—C 1-6 -alkyl, —S(O) 2 CH 3 or —C(O)NR 19 R 20 .

11. A compound according to claim 10 wherein R 16 or R 20 are carboxy.

Assignments (13)
RELEASE OF SECURITY INTEREST Recorded Jan 27, 2021
From: HORIZON TECHNOLOGY FINANCE CORPORATION, AS COLLATERAL AGENT
To: VTV THERAPEUTICS LLC
Reel/Frame 055133/0214 →
SECURITY INTEREST Recorded Apr 18, 2018
From: VTV THERAPEUTICS LLC
To: HORIZON TECHNOLOGY FINANCE CORPORATION, AS COLLATERAL AGENT
Reel/Frame 045969/0774 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA PREVIOUSLY RECORDED AT REEL: 036254 FRAME: 0780. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 24, 2015
From: M&F TTP HOLDINGS LLC, AS COLLATERAL AGENT
To: VTVX HOLDINGS I LLC
Reel/Frame 036675/0407 →
RELEASE OF SECURITY INTEREST Recorded Aug 3, 2015
From: M&F TTP HOLDINGS LLC, AS COLLATERAL AGENT
To: VTVX HOLDINGS II LLC
Reel/Frame 036254/0780 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2015
From: VTVX HOLDINGS I LLC
To: VTV THERAPEUTICS LLC
Reel/Frame 036242/0354 →
CHANGE OF NAME Recorded Jul 30, 2015
From: VTV THERAPEUTICS LLC
To: VTVX HOLDINGS I LLC
Reel/Frame 036236/0165 →
CHANGE OF NAME Recorded Jun 25, 2015
From: TRANSTECH PHARMA, LLC
To: VTV THERAPEUTICS LLC
Reel/Frame 036026/0219 →
SECURITY INTEREST Recorded Feb 26, 2015
From: TRANSTECH PHARMA, LLC
To: M&F TTP HOLDINGS LLC, AS COLLATERAL AGENT
Reel/Frame 035103/0356 →
NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS FOR REEL/FRAME 030982/0803 Recorded Apr 7, 2014
From: M&F TTP HOLDINGS LLC
To: TRANSTECH PHARMA, LLC
Reel/Frame 032621/0860 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2013
From: TRANSTECH PHARMA, INC.
To: TRANSTECH PHARMA, LLC
Reel/Frame 031654/0878 →
SECURITY AGREEMENT Recorded Aug 9, 2013
From: TRANSTECH PHARMA, INC.
To: M&F TTP HOLDINGS LLC C/O MACANDREWS & FORBES HOLDINGS INC.
Reel/Frame 030982/0803 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2012
From: NOVO NORDISK A/S
To: TRANSTECH PHARMA, INC.
Reel/Frame 029112/0134 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2008
From: MURRAY, ANTHONY; LAU, JESPER; VEDSO, PER; KRISTIANSEN, MARIT; JEPPESEN, LONE
To: NOVO NORDISK A/S
Reel/Frame 021211/0545 →